Active ingredientTasimelteonCat. No. P-T018-001CAS 609799-22-6Family · Pharmaceutical analytical standards
Tasimelteon
A melatonin MT1 and MT2 receptor agonist, approved in the United States in 2014 for non-24-hour sleep-wake disorder and in 2020 for night-time sleep disturbances in Smith-Magenis syndrome. This family brings together the active ingredient, metabolites, labelled standards, nitrosamines and other impurities.
Did you know?According to the FDA it was the first treatment approved for non-24-hour disorder, in which the body clock does not keep in step with the day; in Europe it is indicated for totally blind adults.
Go to the active ingredient →Active ingredientTasimelteonCat. No. P-T018-001CAS 609799-22-6
Metabolite(2S)-2-Hydroxy TasimelteonCat. No. P-T018-002CAS 1448344-05-5
Metabolite(3R)-3-Hydroxy TasimelteonCat. No. P-T018-003CAS 1448344-01-1
Metabolite(3S)-3-Hydroxy TasimelteonCat. No. P-T018-004CAS 1448344-03-3
Metabolite2-Hydroxy Tasimelteon O-GlucuronideCat. No. P-T018-005
MetaboliteTasimelteon N-GlucuronideCat. No. P-T018-006
Isotopically labelledTasimelteon-d5Cat. No. P-T018-007CAS 1962124-51-1
NitrosamineN-Nitroso TasimelteonCat. No. P-T018-008
ImpurityTasimelteon Impurity 1Cat. No. P-T018-009CAS 1803286-27-2
ImpurityTasimelteon Impurity 2Cat. No. P-T018-010
ImpurityTasimelteon Impurity 3Cat. No. P-T018-011CAS 1803286-24-9
ImpurityTasimelteon Impurity GCat. No. P-T018-012CAS 251562-65-9No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.